How big is Karyopharm Therapeutics, Inc.?

As of Jun 18, Karyopharm Therapeutics, Inc. has a market capitalization of 37.71 million and reported net sales of 142.13 million with a net profit of -62.52 million over the latest four quarters.

As of Jun 18, Karyopharm Therapeutics, Inc. has a market capitalization of 37.71 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 142.13 million for the latest four quarters, while the net profit for the same period was -62.52 million.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of -186.02 million and total assets of 164.42 million.

What does Karyopharm Therapeutics, Inc. do?

Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company that develops drugs targeting nuclear export for cancer treatment. As of March 2025, it reported net sales of $30 million and a net loss of $23 million, with a market cap of $37.71 million.

Overview:<BR>Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company engaged in the discovery, development, and commercialization of drugs targeting nuclear export for cancer treatment, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 30 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -23 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 37.71 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.54 <BR>Return on Equity: 52.02% <BR>Price to Book: -0.18<BR><BR>Contact Details:<BR>Address: 85 Wells Ave, NEWTON CENTER MA: 02459-3298 <BR>Tel: 1 617 6580600 <BR>Fax: 1 302 6555049 <BR>Website: https://karyopharm.com/

Should I buy, sell or hold Karyopharm Therapeutics, Inc.?

Who are in the management team of Karyopharm Therapeutics, Inc.?

As of March 2022, Karyopharm Therapeutics, Inc.'s management team includes Dr. Michael Kauffman (Co-Founder, CEO, Director), Mr. Barry Greene (Lead Independent Director), Dr. Mansoor Mirza (Director, Clinical Advisor), Ms. Christy Oliger (Director), Mr. Chen Schor (Director), and Mr. Garen Bohlin (Independent Director).

As of March 2022, the management team of Karyopharm Therapeutics, Inc. includes Dr. Michael Kauffman, who serves as the Co-Founder, Chief Executive Officer, and Director. Other key members of the management team are Mr. Barry Greene, the Lead Independent Director; Dr. Mansoor Mirza, who is a Director and Clinical Advisor; Ms. Christy Oliger, a Director; Mr. Chen Schor, a Director; and Mr. Garen Bohlin, an Independent Director.

Is Karyopharm Therapeutics, Inc. overvalued or undervalued?

Karyopharm Therapeutics, Inc. is considered overvalued and risky due to negative valuation metrics and poor stock performance, with a year-to-date return of -43.52% and a five-year decline of -97.66%, contrasting sharply with the S&P 500's gains.

As of 15 March 2018, Karyopharm Therapeutics, Inc. has moved from a grade of does not qualify to risky, indicating increased concerns about its valuation. The company appears to be overvalued given its negative valuation metrics, including a Price to Book Value of -0.19, an EV to EBIT of -1.25, and an EV to EBITDA of -1.26. Compared to peers, Karyopharm's EV to EBITDA ratio of -1.6265 is significantly worse than XOMA Corp.'s -22.9484 and Zevra Therapeutics, Inc.'s 7.4373, highlighting its relative weakness in the industry.<BR><BR>The stock's performance has been notably poor, with a year-to-date return of -43.52% compared to the S&P 500's 12.22%, and a staggering decline of -97.66% over the past five years, while the S&P 500 has gained 96.61%. This stark contrast in returns further reinforces the notion that Karyopharm is overvalued in its current state.

Is Karyopharm Therapeutics, Inc. technically bullish or bearish?

As of August 13, 2025, Karyopharm Therapeutics has a mildly bearish technical outlook, with mixed signals from indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -43.52%.

As of 13 August 2025, the technical trend for Karyopharm Therapeutics, Inc. has changed from bearish to mildly bearish. Currently, the weekly MACD and Bollinger Bands indicate a mildly bullish stance, while the daily moving averages and the weekly KST suggest a mildly bearish outlook. The RSI shows no signal in both weekly and monthly time frames, and Dow Theory reflects a mildly bearish trend on the weekly chart with no trend on the monthly. <BR><BR>In terms of performance, Karyopharm has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -43.52% compared to the S&P 500's 12.22%, and a one-year return of -48.13% versus 17.14% for the benchmark. Overall, the current technical stance is mildly bearish, indicating some weakness despite a few bullish signals.